Search research articles
Contact Us
Filters
Showing results (61-70 of 86) with videos related to
Page
of 9
Sort By:
The Journal of Antibiotics
|
June 1, 1995
Salfredins, new aldose reductase inhibitors produced by Crucibulum sp. RF-3817. I. Fermentation, isolation and structures of salfredins
K Matsumoto, K Nagashima, T Kamigauchi, et al.
The Journal of Antibiotics
|
June 1, 1992
Depudecin: a novel compound inducing the flat phenotype of NIH3T3 cells doubly transformed by ras- and src-oncogene, produced by Alternaria brassicicola
M Matsumoto, S Matsutani, K Sugita, et al.
The Journal of Antibiotics
|
December 1, 1991
Thielocins A1 alpha and A1 beta, novel phospholipase A2 inhibitors from ascomycetes
T Yoshida, S Nakamoto, R Sakazaki, et al.
Blood Cancer Journal
|
September 30, 2017
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
Y Kusano, M Yokoyama, Y Terui, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
November 24, 1999
[Moderate aplastic anemia associated with Crohn's disease during antithymocyte globulin treatment]
M Mori, T Tanaka, Y Akifuji, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 4, 2009
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
D Ennishi, H Asai, Y Maeda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2009
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy
M Kodaira, S Takahashi, S Yamada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
D Ennishi, M Yokoyama, Y Terui, et al.
Leukemia & Lymphoma
|
November 9, 2001
CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: usefulness of in vitro apoptosis in leukemic cells
M Mori, K Hatake, M Tanaka, et al.
Endoscopy
|
March 29, 2001
Rapid worsening of esophageal varices in a patient with small hepatocellular carcinomas after percutaneous ethanol injection therapy
Y Terui, H Togashi, T Matsuo, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 86) with videos related to
Sort By:
Page
of 9
The Journal of Antibiotics
|
June 1, 1995
Salfredins, new aldose reductase inhibitors produced by Crucibulum sp. RF-3817. I. Fermentation, isolation and structures of salfredins
K Matsumoto, K Nagashima, T Kamigauchi, et al.
The Journal of Antibiotics
|
June 1, 1992
Depudecin: a novel compound inducing the flat phenotype of NIH3T3 cells doubly transformed by ras- and src-oncogene, produced by Alternaria brassicicola
M Matsumoto, S Matsutani, K Sugita, et al.
The Journal of Antibiotics
|
December 1, 1991
Thielocins A1 alpha and A1 beta, novel phospholipase A2 inhibitors from ascomycetes
T Yoshida, S Nakamoto, R Sakazaki, et al.
Blood Cancer Journal
|
September 30, 2017
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
Y Kusano, M Yokoyama, Y Terui, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|
November 24, 1999
[Moderate aplastic anemia associated with Crohn's disease during antithymocyte globulin treatment]
M Mori, T Tanaka, Y Akifuji, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 4, 2009
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
D Ennishi, H Asai, Y Maeda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2009
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy
M Kodaira, S Takahashi, S Yamada, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
D Ennishi, M Yokoyama, Y Terui, et al.
Leukemia & Lymphoma
|
November 9, 2001
CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: usefulness of in vitro apoptosis in leukemic cells
M Mori, K Hatake, M Tanaka, et al.
Endoscopy
|
March 29, 2001
Rapid worsening of esophageal varices in a patient with small hepatocellular carcinomas after percutaneous ethanol injection therapy
Y Terui, H Togashi, T Matsuo, et al.
Page
of 9